Colchicine for epidermolysis bullosa acquisita
- PMID: 8632074
- DOI: 10.1016/s0190-9622(96)90013-4
Colchicine for epidermolysis bullosa acquisita
Abstract
Background: Epidermolysis bullosa acquisita (EBA) is a chronic subepidermal blistering disease that is difficult to treat. Recently one patient with severe EBA was described who responded dramatically to colchicine.
Objective: Our purpose was to determine the efficacy of colchicine in the treatment of EBA.
Methods: Four patients with severe EBA refractory to conventional therapy were treated with colchicine 0.6 to 1.5 mg a day for up to 4 years.
Results: In all four patients the lessening of skin fragility and the decrease in spontaneous blister formation were dramatic; few side effects were noted.
Conclusion: Colchicine should be considered in the treatment of EBA.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
